AKS-452 COVID-19 Vaccine Description 2022
AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-CoV-2 viral spike protein receptor-binding domain antigen (Ag) and human IgG1 Fc (SP/RBD-Fc).
The Fc component is designed to enhance immunogenicity by increasing uptake via Fc-receptors (FcγR) on Ag-presenting cells (APCs) and prolonging exposure due to neonatal Fc receptor (FcRn) recycling.
AKS-452 induced approximately 20-fold greater neutralizing IgG titers in mice relative to those induced by SP/RBD without the Fc component and induced comparable long-term neutralizing titers with a single dose vs. two doses.
AKS-452 COVID-19 Vaccine News
October 29, 2021 - Science Direct published an article discussing the biologically-engineered vaccine, AKS-452.
AKS-452 COVID-19 Vaccine Clinical Trial
AKS-452 has been involved in several preclinical studies. The results of these studies supported the initiation of the Phase 1/2 trial.
Clinical Trial NCT04681092: Anti-COVID19 AKS-452 Fusion Protein Vaccine - ACT Study (ACT)
This trial is to determine if AKS-452, a room-temperature stable, Fc-fusion subunit vaccine, can be rapidly and inexpensively manufactured to provide billions of doses per year, especially in regions where the cold chain is difficult to maintain.
To warrant more extensive development towards a phase III clinical study. The study will have a duration of approximately 4 months and will be executed at the University Medical Center Groningen, The Netherlands supported by the subsidizing party Akston Biosciences.